wyeth-v-levine
2 cases — ← All topics
| Case | Title | Lower Court | Docketed | Status | Flags | Tags | Question Presented |
|---|---|---|---|---|---|---|---|
| 21-1238 | Ina Ann Rodman v. Otsuka America Pharmaceutical, Inc. | Ninth Circuit | 2022-03-11 | Denied | Response Waived | 21-cfr-314-80 design-defect drug-labeling expert-testimony failure-to-warn misbranding pharmaceutical-liability post-marketing-surveillance summary-judgment wyeth-v-levine | Whether Ms. Rodman presented admissible evidence of Otsuka's failure to follow post-marketing surveillance and label revision requirements, and whethe… |
| 18-803 | Wendy B. Dolin v. GlaxoSmithKline, LLC, fka SmithKline Beecham Corporation | Seventh Circuit | 2018-12-21 | Denied | Relisted (2) | clinical-trials drug-labeling drug-manufacturer fda-regulations impossibility-preemption labeling-changes preemption truthful-risks unilateral-labeling-changes unilateral-warning wyeth-v-levine | Does federal law prevent a drug manufacturer from enhancing its label to reflect truthful risks revealed in its clinical trials when the relevant FDA … |